In Kessler et al. ([@r1]), the small molecule **BI-2852** is shown to bind---at nanomolar affinity---to KRAS between switch I and II, inhibiting interactions with effectors. Here, we identify an alternative explanation for the inhibitory activity. While investigating the **BI-2852** KRAS complex (Protein Data Bank \[PDB\] code 6GJ8), we noticed, by revealing the molecules in the neighboring unit cell, **BI-2852** induces a KRAS dimer with rotational symmetry. This dimer complex consists of four molecules (two of **BI-2852** and two of KRAS; [Fig. 1*A*](#fig01){ref-type="fig"}).

![Dimer of KRAS with BI-2852. (*A*) Cartoon of BI-2852 KRAS dimer. Lig1 (cyan) and Lig2 (magenta) interact with both Ras1 (beige) and Ras2 (orange). (*B*) KRAS (ribbons) and key side chains are shown. (*C*) Zoom-in of the binding site: salt--bridge interactions shown (dashed lines). (*D*) Lid (green) and Basin (purple) are indicated on Ras1. Both Lig1 and Lig2 are shown on Ras1. The indole rings, colored green and purple, engage the Lid and Basin, respectively. (*E*) Absorbance *A*~280~ plotted as a function of elution volume: KRAS G12D-GppNHp with BI-2852 (orange) and apo KRAS G12D-GppNHp (blue).](pnas.1918164117fig01){#fig01}

To show **BI-2852** induces dimers of KRAS, we performed the following: analysis of the crystal structures to characterize the dimer; performance of size exclusion column chromatography (SEC) experiments using protein with and without **BI-2852**, followed by analysis using native mass spectrometry; and measurement of binding affinity using isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR).

Through structural analysis of PDB code 6GJ8, we identify critical interactions that stabilize the dimer ([Fig. 1](#fig01){ref-type="fig"}). Focusing on the pocket formed about Lig1 (one of two copies of **BI-2852**), the pocket is formed by two KRAS molecules---with one KRAS forming a larger pocket (Basin) and a second KRAS molecule forming a smaller pocket (Lid) ([Fig. 1 *A--D*](#fig01){ref-type="fig"}). There are two salt--bridge interactions about Lig1: Lys5 of Ras1 interacts with Glu3 of Ras2, Asp54 of Ras1 interacts with the amine of Lig1, and the amine of Lig1 also interacts with Glu3 of Ras2 ([Fig. 1*C*](#fig01){ref-type="fig"} and Figshare \[<https://doi.org/10.6084/m9.figshare.11425995>, section 3.1; ref. [@r2]\]). We observe symmetric interactions about Lig2; thus, there are four salt--bridge interactions at the interface.

In the SEC experiment, we observe the formation of a KRAS dimer in solution when **BI-2852** is present and a monomer when ligand is absent ([Fig. 1*E*](#fig01){ref-type="fig"}), and by native mass spectrometry, we confirm their molecular weight (Figshare \[<https://doi.org/10.6084/m9.figshare.11425995>, section 3.3; ref. [@r2]\]). From SPR, where KRAS is a monomer on the sensor surface, we measure an affinity of 22 μM. Moreover, the response is over double the theoretical maximal binding predicted for a 1:1 interaction, implying there are two binding sites (Figshare \[<https://doi.org/10.6084/m9.figshare.11425995>, section 3.4.2; ref. [@r2]\]). Using ITC, we reproduced the affinity values of 720 nM for KRAS G12D-GppHHp with **BI-2852**, consistent with Kessler et al. This increased affinity over that of the SPR data is likely due to the avidity of the two compound binding sites and stabilization of the dimer. We surmise the ligand binds to both the Basin (switch I/II pocket) and the Lid ([Fig. 1*D*](#fig01){ref-type="fig"}). These experimental observations are consistent with a dimer of KRAS stabilized by two molecules of **BI-2852**.

The biological effects of this compound, at least in part, are due to the formation of the KRAS dimer, resulting in enhanced binding affinity (22 μM to 720 nM). Moreover, the dimer occludes the binding footprint of the RAF1 RBD (Figshare \[<https://doi.org/10.6084/m9.figshare.11425995>, Fig. S2; ref. [@r2]\]). To our knowledge, such a structure of KRAS as a dimer has never been observed; albeit, this likely nonfunctional dimer is distinct from a biologically relevant KRAS multimer. The formation of a nonfunctional KRAS dimer seen in structures reported by Kessler et al. reveals a strategy of directly targeting KRAS.
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